Verona Pharma (VRNA) Stock Forecast & Price Target

$38.85 +0.76 (+2.00%)

(As of 11/20/2024 ET)

Verona Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 6 Analyst Ratings

Sell
0

Hold
0

Buy
6

Based on 6 Wall Street analysts who have issued ratings for Verona Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for VRNA.

Consensus Price Target

$43.83
12.83% Upside

According to the 6 analysts' twelve-month price targets for Verona Pharma, the average price target is $43.83. The highest price target for VRNA is $64.00, while the lowest price target for VRNA is $33.00. The average price target represents a forecasted upside of 12.83% from the current price of $38.85.

Get the Latest News and Ratings for VRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Verona Pharma and its competitors.

VRNA Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$43.83	$39.33	$36.00	$32.60
Forecasted Upside	12.83% Upside	12.80% Upside	33.93% Upside	132.03% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Missed Nvidia? Watch this ASAP (Ad)

This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

VRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Verona Pharma Stock vs. The Competition

Type	Verona Pharma	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	12.83% Upside	26,931.60% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent VRNA News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/5/2024	Wells Fargo & Company 3 of 5 stars	T. Fauth Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$50.00 ➝ $64.00	+65.85%
11/5/2024	HC Wainwright 2 of 5 stars		Boost Target	Buy ➝ Buy	$36.00 ➝ $42.00	+10.09%
11/5/2024	Canaccord Genuity Group 1 of 5 stars		Boost Target	Buy ➝ Buy	$37.00 ➝ $44.00	+15.33%
10/9/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$38.00 ➝ $44.00	+39.68%
4/16/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$31.00 ➝ $36.00	+127.85%
3/1/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$33.00	+91.64%
Get the Latest News and Ratings for VRNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
3/20/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$26.00 ➝ $31.00	+66.67%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:45 AM ET.

VRNA Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Verona Pharma is $43.83, with a high forecast of $64.00 and a low forecast of $33.00.
: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRNA shares.
: According to analysts, Verona Pharma's stock has a predicted upside of 12.83% based on their 12-month stock forecasts.
: Verona Pharma has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Verona Pharma more than other "medical" companies. The consensus rating for Verona Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VRNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump won. Buy this coin now. (Ad)

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

This page (NASDAQ:VRNA) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verona Pharma (VRNA) Stock Forecast & Price Target